Cost-effectiveness of niraparib, rucaparib, and olaparib for treatment of platinum-resistant, recurrent ovarian carcinoma.
Sign Up to like & getrecommendations! Published in 2020 at "Gynecologic oncology"
DOI: 10.1016/j.ygyno.2020.02.030
Abstract: BACKGROUND Olaparib was approved on December 19, 2014 by the US FDA as 4th-line therapy (and beyond) for patients with germline BRCA1/2 mutations; rucaparib was approved on December 19, 2016 as 3rd-line therapy (and beyond)… read more here.
Keywords: platinum; cost; pfs month; platinum resistant ... See more keywords